

Publicazioni dal 2002 al 2014

- 1) Farina L, Guidetti A, Spina F, Roncari L, Longoni P, Ravagnani F, Carlo-Stella C, **Corradini P**. Plerixafor 'on demand': results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy+G-CSF. *Bone Marrow Transplant*. 2014 Mar;49(3):453-5. Epub 2013 Dec 9. PubMed PMID: 24317127.
- 2) Anastasia A, Carlo-Stella C, **Corradini P**, Salvi F, Rusconi C, Pulsoni A, Hohaus S, Pregno P, Viviani S, Brusamolino E, Luminari S, Giordano L, Santoro A. Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi. *Br J Haematol*. 2014 Mar 7. PubMed PMID: 24606548.
- 3) Mariotti J, Maura F, Spina F, Roncari L, Doderò A, Farina L, Montefusco V, Carniti C, Sarina B, Patriarca F, Rambaldi A, Onida F, Olivieri A, Zallio F, **Corradini P**. Impact of Cytomegalovirus Replication and CMV serostatus on the Outcome of Patients with B-cell Lymphoma after Allogeneic Stem Cell Transplantation. *Biol Blood Marrow Transplant*. 2014 Feb 27. pii: S1083-8791(14)00102-5. PubMed PMID: 24583412.
- 4) Gambella M, Rocci A, Passera R, Gay F, Omedè P, Crippa C, **Corradini P**, Romano A, Rossi D, Ladetto M, Boccadoro M, Palumbo A. High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib. *Haematologica*. 2014 Feb;99(2):e14-6. PubMed PMID: 24497562; PubMed Central PMCID: PMC3912976.
- 5) **Corradini P**, Carniti C. Molecular methods for detection of minimal residual disease following transplantation in lymphoid and plasma cell disorders. *Methods Mol Biol*. 2014;1109:209-37. PubMed PMID: 24473786.
- 6) Giulia P, **Corradini P**. Autologous stem cell transplantation for T-cell lymphomas. *Semin Hematol*. 2014 Jan;51(1):59-66. Epub 2013 Nov 14. PubMed PMID: 24468317.
- 7) Mauro FR, Molica S, Laurenti L, Cortelezzi A, Carella AM, Zaja F, Chiarenza A, Angrilli F, Nobile F, Marasca R, Musolino C, Brugiatelli M, Picocchi A, Vignetti M, Fazi P, Gentile G, De Propriis MS, Della Starza I, Marinelli M, Chiaretti S, Del Giudice I, Nanni M, Albano F, Cuneo A, Guarini A, Foà R; Gruppo Italiano Malattie EMatologiche dell'Adulto Working Party for Chronic Lymphoproliferative Disorders. Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. *Leuk Res*. 2014 Feb;38(2):198-203. PubMed PMID: 24314589.
- 8) Fanale M, Assouline S, Kuruvilla J, Solal-Céligny P, Heo DS, Verhoef G, **Corradini P**, Abramson JS, Offner F, Engert A, Dyer MJ, Carreon D, Ewald B, Baeck J, Younes A, Freedman AS. Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. *Br J Haematol*. 2014 Jan;164(2):258-65. PubMed PMID: 24219359.
- 9) Olivieri A, Cimminiello M, **Corradini P**, Mordini N, Fedele R, Selleri C, Onida F, Patriarca F, Pavone E, Svegliati S, Gabrielli A, Bresciani P, Nuccorini R, Pascale S, Coluzzi S, Pane F, Poloni A, Olivieri J, Leoni P, Bacigalupo A. Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. *Blood*. 2013 Dec 12;122(25):4111-8. PubMed PMID: 24152907.
- 10) Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, Chiappella A, Baldini L, Rossi G, Pulsoni A, Di Raimondo F, Rigacci L, Pinto A, Galimberti S, Bari A, Rota-Scalabrini D, Ferrari A, Zaja F, Gallamini A, Specchia G, Musto P, Rossi FG, Gamba E, Evangelista A, Vitolo U;

Fondazione Italiana Linfomi. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. *Blood*. 2013 Nov 28;122(23):3759-66. PubMed PMID: 24085766.

- 11) Perrone G, Farina L, **Corradini P**. Current state of art for transplantation paradigms in peripheral T-cell lymphomas. *Expert Rev Hematol*. 2013 Aug;6(4):465-74. PubMed PMID: 23991932.
- 12) Larocca A, Montefusco V, Bringhen S, Rossi D, Crippa C, Mina R, Galli M, Marcatti M, La Verde G, Giuliani N, Magarotto V, Guglielmelli T, Rota-Scalabrini D, Omedé P, Santagostino A, Baldi I, Carella AM, Boccadoro M, **Corradini P**, Palumbo A. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. *Blood*. 2013 Oct 17;122(16):2799-806. PubMed PMID: 23954889.
- 13) Montoto S, **Corradini P**, Dreyling M, Ghielmini M, Kimby E, López-Guillermo A, Mackinnon S, Marcus RE, Salles G, Schouten HC, Sureda A, Dreger P. Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. *Haematologica*. 2013 Jul;98(7):1014-21. PubMed PMID: 23813647; PubMed Central PMCID: PMC3696603.
- 14) Gay F, Magarotto V, Crippa C, Pescosta N, Guglielmelli T, Cavallo F, Pezzatti S, Ferrari S, Liberati AM, Oliva S, Patriarca F, Offidani M, Omedé P, Montefusco V, Petrucci MT, Giuliani N, Passera R, Pietrantuono G, Boccadoro M, **Corradini P**, Palumbo A. Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. *Blood*. 2013 Aug 22;122(8):1376-83. PubMed PMID: 23775712.
- 15) Farina L, Spina F, Guidetti A, Longoni P, Ravagnani F, Dodero A, Montefusco V, Carlo-Stella C, **Corradini P**. Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor. *Leuk Lymphoma*. 2014 Feb;55(2):331-6. PubMed PMID: 23656194.
- 16) Zinzani PL, Viviani S, Anastasia A, Vitolo U, Luminari S, Zaja F, **Corradini P**, Spina M, Brusamolino E, Gianni AM, Santoro A, Botto B, Derenzini E, Pellegrini C, Argnani L. Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. *Haematologica*. 2013 Aug;98(8):1232-6. PubMed PMID: 23645687; PubMed Central PMCID: PMC3729903.
- 17) Passera R, Pollichieni S, Brunello L, Patriarca F, Bonifazi F, Montefusco V, Falda M, Montanari M, Guidi S, Giaccone L, Mordini N, Carella AM, Bavaro P, Milone G, Benedetti F, Ciceri F, Scimè R, Benedetti E, Castagna L, Festuccia M, Rambaldi A, Bacigalupo A, **Corradini P**, Bosi A, Boccadoro M, Bandini G, Fanin R, Bruno B. Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry. *Biol Blood Marrow Transplant*. 2013 Jun;19(6):940-8. PubMed PMID: 23538113.
- 18) Gahrton G, Iacobelli S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, **Corradini P**, Schönland S, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N; EBMT Chronic Malignancies Working Party Plasma Cell Disorders Subcommittee. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. *Blood*. 2013 Jun 20;121(25):5055-63. PubMed PMID: 23482933.
- 19) Petrucci MT, Giraldo P, **Corradini P**, Teixeira A, Dimopoulos MA, Blau IW, Drach J, Angermund R, Allietta N, Broer E, Mitchell V, Bladé J. A prospective, international phase 2 study of bortezomib

- retreatment in patients with relapsed multiple myeloma. *Br J Haematol.* 2013 Mar;160(5):649-59. PubMed PMID: 23293914.
- 20) Spina F, Rezzonico F, Farina L, **Corradini P**. Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia. *Eur J Haematol.* 2013 Apr;90(4):340-4. PubMed PMID: 23281656.
 - 21) Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M, Federico M, Hoskin P, McNamara C, Caligaris-Cappio F, Stilgenbauer S, Marcus R, Trneny M, Dreger P, Montserrat E, Dreyling M; Panel Members of the 1st ESMO Consensus Conference on Malignant Lymphoma. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). *Ann Oncol.* 2013 Mar;24(3):561-76. PubMed PMID: 23175624.
 - 22) Montefusco V, Spina F, Patriarca F, Offidani M, Bruno B, Montanari M, Mussetti A, Sperotto A, Scortechini I, Doderò A, Fanin R, Valagussa P, **Corradini P**. Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation. *Biol Blood Marrow Transplant.* 2013 Mar;19(3):424-8. doi: 10.1016/j.bbmt.2012.10.032. Epub 2012 Nov 8. PubMed PMID: 23142330.
 - 23) Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Pierdominici M, Barbati C, Mortarini R, Devizzi L, Matteucci P, Marchianò A, Lanocita R, Farina L, Doderò A, Tarella C, Di Nicola M, **Corradini P**, Anichini A, Gianni AM. Phase II study of sorafenib in patients with relapsed or refractory lymphoma. *Br J Haematol.* 2012 Jul;158(1):108-19. PubMed PMID: 22571717.
 - 24) Mariotti J, Spina F, Carniti C, Anselmi G, Lucini D, Vendramin A, Pregliasco F, **Corradini P**. Long-term patterns of humoral and cellular response after vaccination against influenza A (H1N1) in patients with hematologic malignancies. *Eur J Haematol.* 2012 Aug;89(2):111-9. PubMed PMID: 22540245.
 - 25) Barosi G, Merlini G, Billio A, Boccadoro M, **Corradini P**, Marchetti M, Massaia M, Tosi P, Palumbo A, Cavo M, Tura S. SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. *Ann Hematol.* 2012 Jun;91(6):875-88. Review. PubMed PMID: 22476884.
 - 26) Corso A, Galli M, Mangiacavalli S, Rossini F, Nozza A, Pascutto C, Montefusco V, Baldini L, Cafro AM, Crippa C, Cazzola M, **Corradini P**. Response-adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression-free survival in transplanted patients with multiple myeloma. *Am J Hematol.* 2012 Feb;87(2):150-4. PubMed PMID: 22189759.
 - 27) Zinzani PL, **Corradini P**, Gallamini A, Grossi A, Lazzarino M, Marchetti M, Martelli M, Rossi G, Vitolo U. Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. *Leuk Lymphoma.* 2012 May;53(5):789-95. Review. PubMed PMID: 21980956.
 - 28) Patriarca F, Einsele H, Spina F, Bruno B, Isola M, Nozzoli C, Nozza A, Sperotto A, Morabito F, Stuhler G, Festuccia M, Bosi A, Fanin R, **Corradini P**. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability. *Biol Blood Marrow Transplant.* 2012 Apr;18(4):617-26. PubMed PMID: 21820394.
 - 29) Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, Cavalli M, Stanevsky A, **Corradini P**, Pezzatti S, Patriarca F, Cavo M, Peccatori J, Catalano L, Carella AM, Cafro AM, Siniscalchi A, Crippa C, Petrucci MT, Yehuda DB, Beggiato E, Di Toritto TC, Boccadoro M, Nagler A, Palumbo A. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. *Blood.* 2012 Jan 26;119(4):933-9; PubMed PMID: 21835953.

- 30) Björkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Musto P, Beksac M, Bosi A, Milone G, **Corradini P**, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Gahrton G. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. *J Clin Oncol*. 2011 Aug 1;29(22):3016-22. Erratum in: *J Clin Oncol*. 2011 Sep 20;29(27):3721. PubMed PMID: 21730266.
- 31) Barosi G, Bosi A, Abbracchio MP, Danesi R, Genazzani A, **Corradini P**, Pane F, Tura S. Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. *Haematologica*. 2011 Jul;96(7):937-42. PubMed PMID: 21719882; PubMed Central PMCID: PMC3128210.
- 32) Spina F, Montefusco V, Crippa C, Citro A, Sammassimo S, Olivero B, Gentili S, Galli M, Guglielmelli T, Rossi D, Falcone AP, Grasso M, Patriarca F, De Muro M, **Corradini P**. Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant. *Leuk Lymphoma*. 2011 Jul;52(7):1262-70. PubMed PMID: 21534872.
- 33) Fracchiolla NS, Todoerti K, Bertazzi PA, Servida F, **Corradini P**, Carniti C, Colombi A, Cecilia Pesatori A, Neri A, Deliliers GL. Dioxin exposure of human CD34+ hemopoietic cells induces gene expression modulation that recapitulates its in vivo clinical and biological effects. *Toxicology*. 2011 Apr 28;283(1):18-23. PubMed PMID: 21296121.
- 34) Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A, Patti C, Parvis G, Ciceri F, Gallamini A, Cortelazzo S, Zoli V, **Corradini P**, Carobbio A, Mulé A, Bosa M, Barbui A, Di Nicola M, Sorio M, Caracciolo D, Gianni AM, Rambaldi A. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. *J Clin Oncol*. 2011 Mar 1;29(7):814-24. PubMed PMID: 21189387.
- 35) **Corradini P**, Sarina B, Farina L. Allogeneic transplantation for Hodgkin's lymphoma. *Br J Haematol*. 2011 Feb;152(3):261-72. Review. PubMed PMID: 21155760.
- 36) Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, Di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, **Corradini P**, Narni F, Spadano A, Pescosta N, Deliliers GL, Ledda A, Cellini C, Caravita T, Tosi P, Baccarani M; GIMEMA Italian Myeloma Network. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. *Lancet*. 2010 Dec 18;376(9758):2075-85. Erratum in: *Lancet*. 2011 Nov 26;378(9806):1846. PubMed PMID: 21146205.
- 37) **Corradini P**, Farina L. Allogeneic transplantation for lymphoma: long-term outcome. *Curr Opin Hematol*. 2010 Nov;17(6):522-30. Review. PubMed PMID: 20717024.
- 38) Doderò A, Crocchiolo R, Patriarca F, Miceli R, Castagna L, Ciceri F, Bramanti S, Frungillo N, Milani R, Crippa F, Fallanca F, Englaro E, **Corradini P**. Pretransplantation [18-F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-Hodgkin lymphoma undergoing reduced-intensity conditioning followed by allogeneic stem cell transplantation. *Cancer*. 2010 Nov 1;116(21):5001-11. PubMed PMID: 20665491.

- 39) Kyriakou C, Canals C, Sibon D, Cahn JY, Kazmi M, Arcese W, Kolbe K, Gorin NC, Thomson K, Milpied N, Niederwieser D, Indrak K, **Corradini P**, Sureda A, Schmitz N. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. *J Clin Oncol*. 2010 May 1;28(13):2227-32. PubMed PMID: 20368570.
- 40) Sarina B, Castagna L, Farina L, Patriarca F, Benedetti F, Carella AM, Falda M, Guidi S, Ciceri F, Bonini A, Ferrari S, Malagola M, Morello E, Milone G, Bruno B, Mordini N, Viviani S, Levis A, Giordano L, Santoro A, **Corradini P**; Gruppo Italiano Trapianto di Midollo Osseo. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. *Blood*. 2010 May 6;115(18):3671-7. PubMed PMID: 20220116.
- 41) Palumbo A, Gay F, Falco P, Crippa C, Montefusco V, Patriarca F, Rossini F, Caltagirone S, Benevolo G, Pescosta N, Guglielmelli T, Bringhen S, Offidani M, Giuliani N, Petrucci MT, Musto P, Liberati AM, Rossi G, **Corradini P**, Boccadoro M. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. *J Clin Oncol*. 2010 Feb 10;28(5):800-7. Erratum in: *J Clin Oncol*. 2010 May 1;28(13):2314. PubMed PMID: 20048187.
- 42) Kroger N, Holler E, Kobbe G, Bornhuser M, Schwerdtfeger R, Baurmann H, Nagler A, Bethge W, Stelljes M, Uharek L, Wandt H, Burchert A, **Corradini P**, Schubert J, Kaufmann M, Dreger P, Wulf GG, Einsele H, Zabelina T, Kvasnicka HM, Thiele J, Brand R, Zander AR, Niederwieser D, de Witte TM. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Blood*. 2009 Dec 17;114(26):5264-70. PubMed PMID: 19812383.
- 43) Vose JM, Ho AD, Coiffier B, **Corradini P**, Khouri I, Sureda A, Van Besien K, Dipersio J. Advances in mobilization for the optimization of autologous stem cell transplantation. *Leuk Lymphoma*. 2009 Sep;50(9):1412-21. Review. PubMed PMID: 19603345.
- 44) Kroger N, Badbaran A, Lioznov M, Schwarz S, Zeschke S, Hildebrand Y, Ayuk F, Atanackovic D, Schilling G, Zabelina T, Bacher U, Klyuchnikov E, Shimoni A, Nagler A, **Corradini P**, Fehse B, Zander A. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. *Exp Hematol*. 2009 Jul;37(7):791-8. PubMed PMID: 19487069.
- 45) Farina L, Carniti C, Dodero A, Vendramin A, Raganato A, Spina F, Patriarca F, Narni F, Benedetti F, Olivieri A, **Corradini P**. Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation. *Haematologica*. 2009 May;94(5):654-62. PubMed PMID: 19377072; PubMed Central PMCID: PMC2675677.
- 46) Dodero A, Carniti C, Raganato A, Vendramin A, Farina L, Spina F, Carlo-Stella C, Di Terlizzi S, Milanese M, Longoni P, Gandola L, Lombardo C, **Corradini P**. Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. *Blood*. 2009 May 7;113(19):4771-9. PubMed PMID: 19211934.
- 47) Bruno B, Rotta M, Patriarca F, Mattei D, Allione B, Carnevale-Schianca F, Sorasio R, Rambaldi A, Casini M, Parma M, Bavaro P, Onida F, Busca A, Castagna L, Benedetti E, Iori AP, Giaccone L, Palumbo A, **Corradini P**, Fanin R, Maloney D, Storb R, Baldi I, Ricardi U, Boccadoro M.

Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. *Blood*. 2009 Apr 2;113(14):3375-82. PubMed PMID: 19064724; PubMed Central PMCID: PMC2665903.

- 48) Montefusco V, Gay F, Spina F, Miceli R, Maniezzo M, Teresa Ambrosini M, Farina L, Piva S, Palumbo A, Boccadoro M, **Corradini P**. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. *Leuk Lymphoma*. 2008 Nov;49(11):2156-62. PubMed PMID: 19021059.
- 49) Rossi G, Andreani A, Morandi P, Marchioni A, **Corradini P**, Cappiello G, Bortolotti M, Qosja A, Manzini C, Ferri C, Richeldi L, Cavazza A. Eosinophilic globules in bronchoalveolar lavage fluid of patients with systemic sclerosis-related interstitial lung disease: a diagnostically useful, previously unreported finding in a retrospective and prospective study, including differential diagnosis with other idiopathic and secondary interstitial lung diseases. *Am J Clin Pathol*. 2008 Dec;130(6):927-33. PubMed PMID: 19019770.
- 50) Patriarca F, Petrucci MT, Bringhen S, Baldini L, Caravita T, **Corradini P**, Corso A, Di Raimondo F, Falcone A, Ferrara F, Morabito F, Musto P, Offidani M, Petrini M, Rizzi R, Semenzato G, Tosi P, Vacca A, Cavo M, Boccadoro M, Palumbo A. Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. *Eur J Haematol*. 2009 Feb;82(2):93-105. PubMed PMID: 19018865.
- 51) Patriarca F, Bacigalupo A, Sperotto A, Isola M, Soldano F, Bruno B, van Lint MT, Iori AP, Santarone S, Porretto F, Pioltelli P, Visani G, Iacopino P, Fanin R, Bosi A; GITMO. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). *Haematologica*. 2008 Oct;93(10):1514-22. PubMed PMID: 18728030.
- 52) Tarella C, Zanni M, Magni M, Benedetti F, Patti C, Barbui T, Pileri A, Boccadoro M, Ciceri F, Gallamini A, Cortelazzo S, Majolino I, Mirto S, **Corradini P**, Passera R, Pizzolo G, Gianni AM, Rambaldi A. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innovative nei linfomi survey. *J Clin Oncol*. 2008 Jul 1;26(19):3166-75. PubMed PMID: 18490650.
- 53) **Corradini P**, Montefusco V. Does the addition of thalidomide to MP or low-intensity SCT improve survival in elderly multiple myeloma patients? *Nat Clin Pract Oncol*. 2008 May;5(5):254-5. PubMed PMID: 18349855.
- 54) Rossi G, Marchioni A, Agostini L, **Corradini P**, Costantini M, Cavazza A. Traumatic neuroma of the bronchi: bronchoscopy and histology of a hitherto unreported lesion. *Am J Surg Pathol*. 2008 Apr;32(4):640-1. PubMed PMID: 18317355.
- 55) Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, Pulsoni A, Musso M, Liberati AM, Olivieri A, Gallamini A, Pogliani E, Rota Scalabrini D, Callea V, Di Raimondo F, Pavone V, Tucci A, Cortelazzo S, Levis A, Boccadoro M, Majolino I, Pileri A, Gianni AM, Passera R, **Corradini P**, Tarella C; Gruppo Italiano Trapianto di Midollo Osseo (GITMO); Intergruppo Italiano Linfomi (IIL). Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. *Blood*. 2008 Apr 15;111(8):4004-13. PubMed PMID: 18239086.
- 56) Gahrton G, Iacobelli S, Bandini G, Björkstrand B, **Corradini P**, Crawley C, Hegenbart U, Morgan G, Kröger N, Schattenberg A, Schönland SO, Verdonck LF, Volin L, de Witte T, Niederwieser D; Myeloma Subcommittee of the EBMT. Peripheral blood or bone marrow cells in reduced-intensity

or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma. *Haematologica*. 2007 Nov;92(11):1513-8. PubMed PMID: 18024400.

- 57) Palumbo A, Falco P, **Corradini P**, Falcone A, Di Raimondo F, Giuliani N, Crippa C, Ciccone G, Omedè P, Ambrosini MT, Gay F, Bringhen S, Musto P, Foà R, Knight R, Zeldis JB, Boccadoro M, Petrucci MT; GIMEMA--Italian Multiple Myeloma Network. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. *J Clin Oncol*. 2007 Oct 1;25(28):4459-65. Epub 2007 Sep 4. PubMed PMID: 17785703.
- 58) Paolo C, Lucia F, Anna D. Hematopoietic stem cell transplantation in peripheral T-cell lymphomas. *Leuk Lymphoma*. 2007 Aug;48(8):1496-501. Review. PubMed PMID: 17701579.
- 59) **Corradini P**, Carrabba MG, Farina L. Molecular methods used for the detection of autologous graft contamination in lymphoid disorders. *Methods Mol Med*. 2007;134:179-96. PubMed PMID: 17666751.
- 60) Farina L, **Corradini P**. Current role of allogeneic stem cell transplantation in follicular lymphoma. *Haematologica*. 2007 May;92(5):580-2. PubMed PMID: 17488679.
- 61) Majolino I, Davoli M, Carnevalli E, Locasciulli A, Di Bartolomeo P, Scimè R, **Corradini P**, Selleri C, Narni F, Musso M, Bregni M, Olivieri A, De Fabritiis P, Pogliani L, Arbelaez JE, Ruscio C, Bacigalupo A; Gitmo Institutions. Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma. *Leuk Lymphoma*. 2007 Apr;48(4):759-66. PubMed PMID: 17454635.
- 62) Carlo-Stella C, Guidetti A, Di Nicola M, Lavazza C, Cleris L, Sia D, Longoni P, Milanesi M, Magni M, Nagy Z, **Corradini P**, Carbone A, Formelli F, Gianni AM. IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3. *Cancer Res*. 2007 Apr 1;67(7):3269-75. PubMed PMID: 17409435.
- 63) Giaccone L, Sorasio R, Patriarca F, Mattei D, Montefusco V, Peccatori J, Carnevale-Schianca F, Petrucci MT, Milone G, Guidi S, Rotta M, Fanin R, **Corradini P**, Boccadoro M, Bruno B. Bortezomib after allografting in multiple myeloma: association between neurotoxicity and cyclosporine treatment. *Biol Blood Marrow Transplant*. 2007 Apr;13(4):497-9. PubMed PMID: 17382258.
- 64) Secondino S, Carrabba MG, Pedrazzoli P, Castagna L, Spina F, Grosso F, Bertuzzi A, Bay JO, Siena S, **Corradini P**, Niederwieser D, Demirer T; European Group for Blood and Marrow Transplantation Solid Tumors Working Party. Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation. *Haematologica*. 2007 Mar;92(3):418-20. PubMed PMID: 17339195.
- 65) Bruno B, Sorasio R, Patriarca F, Montefusco V, Guidi S, Busca A, Scimé R, Console G, Milone G, Marotta G, Dominietto A, Giaccone L, Rotta M, Falda M, Bacigalupo A, Bosi A, **Corradini P**, Fanin R, Pollichieni S, Boccadoro M; Gruppo Italiano Trapianto Midollo Osseo. Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma. *Eur J Haematol*. 2007 Apr;78(4):330-7. Epub 2007 Feb 27. PubMed PMID: 17331132.
- 66) Ciceri F, Bonini C, Markt S, Zappone E, Servida P, Bernardi M, Pescarollo A, Bondanza A, Peccatori J, Rossini S, Magnani Z, Salomoni M, Benati C, Ponzoni M, Callegaro L, **Corradini P**, Bregni M, Traversari C, Bordignon C. Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. *Blood*. 2007 Jun 1;109(11):4698-707. Epub 2007 Feb 27. PubMed PMID: 17327416.

- 67) Bruno B, Patriarca F, Sorasio R, Mattei D, Montefusco V, Peccatori J, Bonifazi F, Petrucci MT, Milone G, Guidi S, Giaccone L, Rotta M, Fanin R, Boccadoro M, **Corradini P**; Gruppo Italiano Trapianti di Midollo. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. *Haematologica*. 2006 Jun;91(6):837-9. PubMed PMID: 16769588.
- 68) Carlo-Stella C, Guidetti A, Di Nicola M, Longoni P, Cleris L, Lavazza C, Milanese M, Milani R, Carrabba M, Farina L, Formelli F, Gianni AM, **Corradini P**. CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice. *Exp Hematol*. 2006 Jun;34(6):721-7. PubMed PMID: 16728276.
- 69) van de Donk NW, Kröger N, Hegenbart U, **Corradini P**, San Miguel JF, Goldschmidt H, Perez-Simon JA, Zijlmans M, Raymakers RA, Montefusco V, Ayuk FA, van Oers MH, Nagler A, Verdonck LF, Lokhorst HM. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. *Blood*. 2006 Apr 15;107(8):3415-6. PubMed PMID: 16597603.
- 70) Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, **Corradini P**, Carreras E, Devergie A, Guglielmi C, Kolb HJ, Niederwieser D; Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). *Haematologica*. 2006 Apr;91(4):513-21. PubMed PMID: 16533723.
- 71) Peccatori J, Barkholt L, Demirer T, Sormani MP, Bruzzi P, Ciceri F, Zambelli A, Da Prada GA, Pedrazzoli P, Siena S, Massenkeil G, Martino R, Lenhoff S, **Corradini P**, Rosti G, Ringden O, Bregni M, Niederwieser D; European Bone Marrow Transplantation Solid Tumor Working Party. Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. *Cancer*. 2005 Nov 15;104(10):2099-103. PubMed PMID: 16220555.
- 72) Doderio A, Carrabba M, Milani R, Rizzo E, Raganato A, Montefusco V, Farina L, Milanese M, Longoni P, Carlo-Stella C, **Corradini P**. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. *Exp Hematol*. 2005 Aug;33(8):920-7. PubMed PMID: 16038785.
- 73) Vacca A, Scavelli C, Montefusco V, Di Pietro G, Neri A, Mattioli M, Bicciato S, Nico B, Ribatti D, Dammacco F, **Corradini P**. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. *J Clin Oncol*. 2005 Aug 10;23(23):5334-46. PubMed PMID: 15939924.
- 74) **Corradini P**, Farina L. Immune-mediated attack in relapsed Hodgkin's lymphoma. *Lancet*. 2005 Jun 4-10;365(9475):1906-8. PubMed PMID: 15936404.
- 75) Patriarca F, Sperotto A, Damiani D, Morreale G, Bonifazi F, Olivieri A, Ciceri F, Milone G, Cesaro S, Bandini G, Dini G, **Corradini P**, Fanin R. Infliximab treatment for steroid-refractory acute graft-versus-host disease. *Haematologica*. 2004 Nov;89(11):1352-9. PubMed PMID: 15531458.
- 76) Barosi G, Boccadoro M, Cavo M, **Corradini P**, Marchetti M, Massaia M, Merlini G, Tosi P, Tura S; Italian Society of Hematology; Italian Society of Experimental Hematology; Italian Group for Bone Marrow Transplantation. Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian

Group for Bone Marrow Transplantation (GITMO). *Haematologica*. 2004 Jun;89(6):717-41. Review. PubMed PMID: 15194540.

- 77) **Corradini P**, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M, Narni F, Patriarca F, Boccadoro M, Benedetti F, Rambaldi A, Gianni AM, Tarella C. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. *J Clin Oncol*. 2004 Jun 1;22(11):2172-6. PubMed PMID: 15169805.
- 78) **Corradini P**, Ladetto M, Zallio F, Astolfi M, Rizzo E, Sametti S, Cuttica A, Rosato R, Farina L, Boccadoro M, Benedetti F, Pileri A, Tarella C. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. *J Clin Oncol*. 2004 Apr 15;22(8):1460-8. PubMed PMID: 15084619.
- 79) Carlo-Stella C, Di Nicola M, Milani R, Guidetti A, Magni M, Milanese M, Longoni P, Matteucci P, Formelli F, Ravagnani F, **Corradini P**, Gianni AM. Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers. *Blood*. 2004 May 1;103(9):3287-95. Epub 2004 Jan 15. PubMed PMID: 14726397.
- 80) Ladetto M, Mantoan B, Ricca I, Astolfi M, Drandi D, Compagno M, Vallet S, dell'Aquila M, Alfarano A, Rossatto P, Rocci A, Vitolo U, **Corradini P**, Boccadoro M, Tarella C. Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone. *Exp Hematol*. 2003 Sep;31(9):784-8. PubMed PMID: 12962724.
- 81) Martino R, Giralt S, Caballero MD, Mackinnon S, **Corradini P**, Fernández-Avilés F, San Miguel J, Sierra J. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study. *Haematologica*. 2003 May;88(5):555-60. PubMed PMID: 12745275.
- 82) **Corradini P**, Cavo M, Lokhorst H, Martinelli G, Terragna C, Majolino I, Valagussa P, Boccadoro M, Samson D, Bacigalupo A, Russell N, Montefusco V, Voena C, Gahrton G; Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. *Blood*. 2003 Sep 1;102(5):1927-9. PubMed PMID: 12738666.
- 83) Ladetto M, Drandi D, Compagno M, Astolfi M, Volpato F, Voena C, Novarino A, Pollio B, Addeo A, Ricca I, Falco P, Cavallo F, Vallet S, **Corradini P**, Pileri A, Tamponi G, Palumbo A, Bertetto O, Boccadoro M, Tarella C. PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapy. *J Clin Oncol*. 2003 Apr 1;21(7):1398-403. PubMed PMID: 12663733.
- 84) Gianni AM, Magni M, Martelli M, Di Nicola M, Carlo-Stella C, Pilotti S, Rambaldi A, Cortelazzo S, Patti C, Parvis G, Benedetti F, Capria S, **Corradini P**, Tarella C, Barbui T. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). *Blood*. 2003 Jul 15;102(2):749-55. Epub 2003 Mar 27. PubMed PMID: 12663455.
- 85) Dodero A, Perfetti V, Ciceri F, **Corradini P**. Clinical and molecular remission following reduced intensity conditioning and allogeneic transplantation in a patient with refractory multiple myeloma. *Haematologica*. 2002 Dec;87(12):ECR41. PubMed PMID: 12495912.

- 86) Ladetto M, **Corradini P**, Vallet S, Benedetti F, Vitolo U, Martelli M, Brugiattelli M, Coser P, Perrotti A, Majolino I, Fioritoni G, Morandi S, Musso M, Zambello R, Chisesi T, Di Renzo N, Vivaldi P, De Crescenzo A, Gallamini A, Salvi F, Santini G, Boccomini C, Sorio M, Astolfi M, Drandi D, Pileri A, Tarella C. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). *Blood*. 2002 Sep 1;100(5):1559-65. PubMed PMID: 12176870.
- 87) Voena C, Locatelli G, Castellino C, Omedè P, Ladetto M, Zappone E, Milani R, Perfetti V, Boccadoro M, Pileri A, Lusso P, Villa C, Malnati M, **Corradini P**. Qualitative and quantitative polymerase chain reaction detection of the residual myeloma cell contamination after positive selection of CD34+ cells with small- and large-scale Miltenyi cell sorting system. *Br J Haematol*. 2002 Jun;117(3):642-5. PubMed PMID: 12028036.
- 88) Bregni M, Doderò A, Peccatori J, Pescarollo A, Bernardi M, Sassi I, Voena C, Zaniboni A, Bordignon C, **Corradini P**. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. *Blood*. 2002 Jun 1;99(11):4234-6. PubMed PMID: 12010834.
- 89) **Corradini P**, Tarella C, Olivieri A, Gianni AM, Voena C, Zallio F, Ladetto M, Falda M, Lucesole M, Doderò A, Ciceri F, Benedetti F, Rambaldi A, Sajevo MR, Tresoldi M, Pileri A, Bordignon C, Bregni M. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. *Blood*. 2002 Jan 1;99(1):75-82. PubMed PMID: 11756155.